News coverage about Nevro Corp. (NYSE:NVRO) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nevro Corp. earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 46.3672869572822 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

NVRO has been the subject of several research reports. BidaskClub raised shares of Nevro Corp. from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. ValuEngine downgraded shares of Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Wednesday, May 24th. Northland Securities reissued a “buy” rating and issued a $96.00 price target on shares of Nevro Corp. in a research report on Tuesday, May 9th. Zacks Investment Research raised shares of Nevro Corp. from a “strong sell” rating to a “buy” rating and set a $96.00 price target for the company in a research report on Wednesday, August 2nd. Finally, J P Morgan Chase & Co reissued an “overweight” rating and issued a $102.00 price target on shares of Nevro Corp. in a research report on Monday, July 3rd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $100.57.

Nevro Corp. (NYSE:NVRO) traded up 1.27% during mid-day trading on Friday, reaching $81.90. 303,020 shares of the company traded hands. The company’s 50-day moving average is $82.27 and its 200-day moving average is $85.24. Nevro Corp. has a 12-month low of $65.82 and a 12-month high of $106.93. The stock’s market capitalization is $2.41 billion.

Nevro Corp. (NYSE:NVRO) last posted its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.11. The firm had revenue of $78.02 million during the quarter, compared to the consensus estimate of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. Nevro Corp.’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.31) EPS. Equities analysts predict that Nevro Corp. will post ($1.17) earnings per share for the current fiscal year.

In other Nevro Corp. news, CFO Andrew H. Galligan sold 7,500 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $75.30, for a total value of $564,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.10% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Nevro Corp. (NVRO) Receiving Somewhat Positive News Coverage, Study Shows” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://theolympiareport.com/2017/08/12/nevro-corp-nvro-receiving-somewhat-positive-news-coverage-study-shows.html.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.